• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the Children’s Oncology Group (COG) has opened enrollment in a Phase I trial with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter